By Julie Steenhuysen

CHICAGO (Reuters) -A single infusion of CRISPR Therapeutics’ experimental gene therapy was safe and reduced levels of harmful LDL cholesterol and triglycerides by half in four people taking the highest dose, raising hope for a one-time treatment.

“We’ve never had anything that could lower both LDL and triglycerides by around 50%,” said Cleveland Clinic cardiologist Dr. Steven Nissen, lead researcher of the first-in-human study of the therapy.

Although still very early in development, if future trials prove the treatment, CTX310, to be safe and effective, it could be practice-changing, said Cleveland Clinic’s Dr. Luke Laffin, the study’s co-leader.

“Rather than a once-daily pill or monthly injection, this therapy would potentially offer a one-time infusion that is s

See Full Page